top of page
Prescription Drugs_edited.jpg

Our mission

We support patients and their families by providing medical information based on scientific evidence
エビデンスに基づく医療情報の提供を通じて，病気に苦しむ患者とその家族を支えること

サンプル

Our service

1

We support the entry of global biotech startup into the Japan
海外バイオベンチャーの日本参入をサポート

Prior to initiating the clinical development in Japan, we will support interviews and advisory board meetings with Japanese key thought leaders (KTLs).

日本での臨床開発に先立ち，国内のKTLs（Key Thought Leaders）とのインタビューやアドバイザーボード会議をサポート致します。

2

We support biotech startups in building relationships and sharing information with healthcare professionals
スタートアップ企業，再生医療ベンチャーのメディカルエンゲージメント活動をサポート

Eighteen months before launch in Japan market, we'll ensure impactful medical engagement activities in compliance with Japanese regulations and compliance standards.

日本の法令や各コンプライアンス規則に従い，上市18か月前からの効果的なメディカルエンゲージメント​活動をサポート​致します。​

3

We support access to reliable medical information on therapies not approved in Japan, empowering patients and healthcare professionals to make informed decisions.
国内未承認薬・治療法の情報の提供

Committed to protecting the rights and interests of patients in Japan, we provide trusted information on the efficacy and safety of unapproved drugs and treatment options.

日本に住む患者の権利と利益を守るために，国内未承認薬・治療法の有効性と安全性に関する最新情報を提供致します。

Contact

Thanks for submitting!

CEO　代表取締役​

Masaki Kawamura, DVM, PhD　川村 正起

​​

略歴

北海道大学・獣医学部卒（博士），ライス大学（リサーチフェロー），ベイラー医科大学（客員研究員），武田薬品工業（株）・創薬研究本部（主席研究員）・米国研究開発センター（リサーチディレクター），メディカルアフェアーズ部（サイエンティフィックディレクター），サンファーマ（株）メディカルアフェアーズ部長

​

Publication

  1. Igarashi A, Nakagawa H, Morita A, Okubo Y, Sano S, Imafuku S, Tada Y, Honma M, Mendelsohn A, Kawamura M※, Ohtsuki M. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results after 64 weeks of a phase 3 study (reSURFACE 1), J Dermatol. 2021;00:1–11. https://doi.org/10.1111/1346-8138.15789, ※Corresponding Author

  2. Imafuku S, Nakagawa H, Igarashi A, Morita A, Okubo Y, Sano S, Tada Y, Nemoto O, Rozzo S, Kawamura M※, Ohtsuki M. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1), J Dermatol. 2021;00:1–9. https://doi.org/10.1111/1346-8138.15763, ※Corresponding Author

  3. Tanaka S, Harada S, Hiramatsu N, Nakaya R and Kawamura M. Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab, anti-GM-CSF antibody, in healthy Japanese and white men. Int J Clin Pharmacol Ther. 2018 Nov;56(11):507-517.

  4. Shinozawa E, and Kawamura M. Anti-thrombotic effect of a factor Xa inhibitor TAK-442 in a rabbit model of arteriovenous shunt thrombosis stimulated with tissue factor. BMC Res Notes. 2018; 11: 776.

  5. Nishimura I, Ichikawa S, Mikami M, Ishitoya H, Motomura T, Kawamura M, Linneweber J, Glueck J, Shinohara T, Nosé Y. Evaluation of floating impeller phenomena in a Gyro centrifugal pump. Biomed Mater Eng. 2013;23(1-2):49-55.

  6. Konishi N, Hiroe K, Kawamura M. Effects of fondaparinux and a direct factor Xa inhibitor TAK-442 on platelet-associated prothrombinase in the balloon-injured artery of rats. J Cardiovasc Pharmacol. 2011 Feb;57(2):201-6.

  7. Konishi N, Hiroe K, Kawamura M. Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data. Nihon Yakurigaku Zasshi. 2010 Aug;136(2):88-92.

  8. Konishi N, Hiroe K, Kawamura M. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding. Thromb Haemost. 2010 Sep;104(3):504-13.

  9. Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, Kubo K., Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. J Cardiovasc Pharmacol. 2010 Aug;56(2):156-61.

  10. Fujimoto T, Imaeda Y, Konishi N, Hiroe K, Kawamura M, Textor GP, Aertgeerts K, Kubo K.Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor.  J Med Chem. 2010 May 13;53(9):3517-31.

  11. Konishi N, Hiroe K, Kawamura M. Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. Thromb Res. 2010 Aug;126(2):124-9.

  12. Fujimoto T, Tobisu M, Konishi N, Kawamura M, Tada N, Takagi T, Kubo K. Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one. Bioorg Med Chem. 2009 Dec 1;17(23):7993-8002.

  13. Imaeda Y, Kuroita T, Sakamoto H, Kawamoto T, Tobisu M, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors. J Med Chem. 2008 Jun 26;51(12):3422-36.

  14. Imaeda Y, Kawamoto T, Tobisu M, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K.Discovery of piperazinylimidazo[1,2-a]pyridines as novel S4 binding elements for orally active factor Xa inhibitors. Bioorg Med Chem. 2008 Mar 15;16(6):3125-40.

  15. Imaeda Y, Miyawaki T, Sakamoto H, Itoh F, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2243-60.

  16. Nishimura I, Ichikawa S, Mikami M, Ishitoya H, Motomura T, Kawamura M, Linneweber J, Glueck J, Shinohara T, Nosé Y, Nishimura I. Evaluation of floating impeller phenomena in a gyro centrifugal pump. ASAIO J. 2003 Nov-Dec;49(6):744-7.

  17. Motomura T, Maeda T, Kawahito S, Matsui T, Ichikawa S, Ishitoya H, Kawamura M, Shinohara T, Sato K, Kawaguchi Y, Taylor D, Oestmann D, Glueck J, Nosé Y. Development of silicone rubber hollow fiber membrane oxygenator for ECMO. Artif Organs. 2003 Nov;27(11):1050-3.

  18. Kawahito S, Maeda T, Motomura T, Ishitoya H, Takano T, Nonaka K, Linneweber J, Ichikawa S, Kawamura M, Hanazaki K, Glueck J, Nosé Y. Hemolytic characteristics of oxygenators during clinical extracorporeal membrane oxygenation. ASAIO J. 2002 Nov-Dec;48(6):636-9.

  19. Ishitoya H, Kawamura M, Linneweber J, Motomura T, Ichikawa S, Nishimura I, Glueck J, Shinohara T, Nosé Y. Titania gel reduces thrombin generation. Artif Organs. 2002 Nov;26(11):959-63.

  20. Motomura T, Maeda T, Kawahito S, Matsui T, Ichikawa S, Ishitoya H, Kawamura M, Nishimura I, Shinohara T, Oestmann D, Glueck J, Kawaguchi Y, Sato K, Nosé Y. Extracorporeal membrane oxygenator compatible with centrifugal blood pumps. Artif Organs. 2002 Nov;26(11):952-8.

  21. Kawahito S, Haraguchi S, Maeda T, Motomura T, Takano T, Nonaka K, Linneweber J, Ichikawa S, Kawamura M, Ishitoya H, Glueck J, Sato K, Nosé Y. Preclinical evaluation of a new hollow fiber silicone membrane oxygenator for pediatric cardiopulmonary bypass: ex-vivo study. Ann Thorac Cardiovasc Surg. 2002 Feb;8(1):7-11.

  22. Kitamura S, Fukushi H, Miyawaki T, Kawamura M, Konishi N, Terashita Z, Naka T. Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: synthesis and pharmacological evaluation of 2-oxopiperazine derivatives. J Med Chem. 2001 Jul 19;44(15):2438-50.

  23. Kitamura S, Fukushi I, Miyawaki T, Kawamura M, Terashita E, Naka T. Orally active GPIIb/IIIa antagonists: synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4. Chem Pharm Bull (Tokyo). 2001 Mar;49(3):268-77.

  24. Kitamura S, Fukushi H, Miyawaki T, Kawamura M, Terashita Z, Sugihara H, Naka T. Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acids.Chem Pharm Bull (Tokyo). 2001 Mar;49(3):258-67.

  25. Sugihara H, Fukushi H, Miyawaki T, Imai Y, Terashita Z, Kawamura M, Fujisawa Y, Kita S. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide. J Med Chem. 1998 Feb 12;41(4):489-502.

  26. Kawamura M, Tsuji N, Moriya N, Terashita Z. Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. Thromb Res. 1997 May 15;86(4):275-85.

  27. Kawamura M, Imura Y, Moriya N, Kita S, Fukushi H, Sugihara H, Nishikawa K, Terashita Z. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.J Pharmacol Exp Ther. 1996 Apr;277(1):502-10.

  28. Terashita Z, Imura Y, Kawamura M, Kato K, Nishikawa K. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Thromb Res. 1995 Mar 1;77(5):411-21. Erratum in: Thromb Res 1996 Oct 15;84(2):144. Thromb Res 1996 Jul 1;83(1):113-5.

  29. Kim S, Kawamura M, Wanibuchi H, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Iwao H. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation. 1995 Jul 1;92(1):88-95.

  30. Kawamura M, Kitayoshi T, Terashita Z, Fujiwara S, Takatani M, Nishikawa K. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs. J Lipid Mediat Cell Signal. 1994 May;9(3):255-65.

  31. Kawamura M, Terashita Z, Okuda H, Imura Y, Shino A, Nakao M, Nishikawa K. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats.  J Pharmacol Exp Ther. 1993 Sep;266(3):1664-9.

  32. Kawamura M, Terashita Z, Imura Y, Shino A, Nishikawa K. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. Thromb Res. 1993 May 15;70(4):281-93.

  33. Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992 Feb;260(2):748-55.

  34. Shibouta Y, Terashita Z, Imura Y, Shino A, Kawamura M, Ohtsuki K, Ohkawa S, Nishikawa K, Fujiwara Y. Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats. Kidney Int. 1991 May;39(5):920-9.

​

bottom of page